Making them pay is important but it’s not going to stop drugmakers from endangering public health.
Academic rigour, journalistic flair
Articles on Johnson & Johnson
Displaying 1 - 20 of 23 articles
On the horizon: A new omicron-focused version of the Moderna vaccine that may offer longer protection and a stronger immune response.
After battling drug manufacturers and distributors in court for years, local and state governments are about to receive a windfall that could expand access to treatments that can save lives.
As boosters are authorized for all three COVID-19 shots available in the US, the ability to swap out vaccine types looks to be a boon to the immune system.
Your body produces antibodies after an infection or vaccine, but these slowly decline over time. New Johnson & Johnson data sheds light on the duration of protection and the need for booster shots.
As many teens and adults in the US restart their social lives, parents of children under the age of 12 wonder when their kids will also be able to experience the freedom that comes with vaccination.
South Africa has clearly suffered the consequences of poor strategic decisions to this point. It doesn’t need to continue along these lines.
COVID-19 has exacerbated a backlog of domestic and foreign drug manufacturing inspections that the FDA is still too short-staffed to adequately deal with.
The CDC first paused, then unpaused, the administration of the Johnson & Johnson COVID-19 vaccine due to concerns about blood clots. But what are those clots, and how do they form?
Vaccine manufacturing is complex, with lots of potential points for errors. But it also has extensive quality control checks and approvals.
Good news for children and young people, bad news for Johnson & Johnson.
Divisions among Catholics have created doubts about the moral acceptability of one of the COVID-19 vaccines. An expert explains why there isn’t one ‘Catholic view’ on the issue.
Religious opposition over a link to abortions performed decades ago and misunderstandings about effectiveness could lead to a nightmare of angry patients and wasted vaccine.
Two experts explain why the UK’s vaccine programme has been a success, while abroad China, Russia and India use vaccine supplies to increase their soft power.
The Johnson & Johnson vaccine is different from the Moderna and Pfizer vaccines in a few important ways that could make it a huge help to global vaccination efforts.
Vaccine developers pledge to create boosters that can better handle the new variants of the virus, and new data gives reassurance on the Oxford vaccine.
Both vaccines appear to reduce the risk of developing COVID-19, and so could be approved later this year.
We should applaud drug companies for developing COVID-19 vaccines in record time, but let’s not be under any illusion about the profits that are motivating them.
About 1 in 4 people prescribed an opioid for pain end up abusing it. New methods to reduce the need for opioids after surgery have been shown to work – and thus minimize the need for such drugs.
Asbestos litigation is the number one source of tort claims in the US, with many people decrying the filing of so many claims. But there’s a reason the claims persist. Asbestos isn’t going anywhere.
Job Board
-
Associate Professor, Occupational Therapy
-
GRAINS RESEARCH AND DEVELOPMENT CORPORATION CHAIRPERSON
-
Technical Skills Laboratory Officer
-
Faculty of Law - Academic Appointment Opportunities
-
Audience Development Coordinator (fixed-term maternity cover)
Top contributors
-
Associate Professor of Biology, Rochester Institute of Technology
-
Professor of Operations Management & Business Analytics, Carey Business School, Johns Hopkins University
-
Professor of Bioethics, Macquarie University
-
Pro Vice-Chancellor: Climate, Sustainability and Inequality and Director: Southern Centre for Inequality Studies., University of the Witwatersrand
-
Ezintsha, Faculty of Health Sciences, University of the Witwatersrand, University of the Witwatersrand
-
Chair of Social Security Systems Administration and Management Studies, Adjunct Professor in the School of Governance, University of the Witwatersrand
-
Lecturer, Graphic Design, Edinburgh Napier University
-
Joel Lexchin is a Friend of The Conversation.
Professor Emeritus of Health Policy and Management, York University, Canada
-
Professor of Nursing Research, Skin Integrity and Wound Care, The University of Melbourne
-
Distinguished Professor of Pharmacy Practice, University of Connecticut
-
Professor of Political Science, USC Dornsife College of Letters, Arts and Sciences
-
Clinical Assistant Professor of Anesthesiology, University of Southern California
-
Principal Lecturer, Microbiology and Biomedical Science Practice, Fellow of the Institute of Biomedical Science, University of Brighton
-
Associate Professor of History, University at Buffalo
-
Dean Faculty of Health Sciences and Professor of Vaccinology at University of the Witwatersrand; and Director of the SAMRC Vaccines and Infectious Diseases Analytics Research Unit, University of the Witwatersrand
